This is the sixth in our series of posts based on the OHE seminar and summarises the remarks of Dr Matthias Liefner of Simon Kucher and Partners.
In Europe, pricing of biosimilars already has begun to affect the market for biologics. For example, France’s compulsory price discounts for generic drugs have been applied to EPO and somatropin biosimilars; the ensuing mandatory price reductions for the originator in the French system have made prices roughly equivalent. In German, EPO and somatropin are included in the reference price system. Quotas and guidelines enforce the use of biosimilars regionally and tenders are likely to be applied to biologics in future. In the UK, where the Primary Care Trusts decide formularies, price is expected to be an important factor.
Across Europe, however, the focus of payers on price is moderated by concerns -- particularly among physicians -- about the safety and side-effect profiles of biosimilars. The relative weight of price versus potential risk may vary with the disease area targeted by the biologic, however. For example, since growth hormone is given primary to children and effects are visible only over the longer term, tolerance of risk and reduced efficacy is lower. EPO and insulin, in comparison, are primarily adult medications and their effects are visible immediately. Payers are more likely to support the use of biosimilars in such cases.
The potential effect of price controls on biologics markets is illustrated by EPO in Germany. A cascade of price reductions followed the creation of a fixed reference price (FRP) group in 2007 and the entry of three biosimilars later that year – at 30% below the originator price. A price reduction by the originator was followed by further price reductions by the biosimilars and then again by one of the originators.
Dr Liefner described what factors could determine whether price wars appear in other biosimilars markets. These are summarised in the graphic. He concluded that the extent to which these dynamics operate depends in part on the originator’s pricing strategy and on reservations, by payers and physicians, about risks – a situation likely to change as experience increases comfort with biosimilars.
Source: Simon Kucher and Partners (click graphic to enlarge)
Dr Matthias Liefner is a Director in the Life Sciences Division at Simon Kucher and Partners.
Publication now available for download: Mattison, N., Mestre-Ferrandiz, J. and Towse, A. eds (2010) Biosimilars: How much entry and price competition will result? London: Office of Health Economics.
Posted in Biosimilars, Competition, Pricing and Reimbursement | Tagged